GlassScriptPhysician profile
James Philippe Bota
NPI 1396007985
$8,744.02
in general payments reported to CMS, 2019-2025
35 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $902 · 2021: $1,308 · 2022: $1,006 · 2023: $1,193 · 2024: $1,395 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,805.77 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $589.73 | 2019-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $567.04 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Amgen INC. | $546.09 | 2019-2025 | Otezla, Enbrel, Otezla |
| Biofrontera INC. | $356.51 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $338.97 | 2019-2023 | Libtayo |
| Janssen Biotech, INC. | $334.87 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $329.80 | 2019-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $319.43 | 2019-2025 | |
| Leo Pharma INC. | $297.33 | 2019-2025 | Adbry |
| Incyte Corporation | $189.82 | 2021-2024 | Opzelura |
| Dermira, INC. | $181.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $157.33 | 2022-2023 | Sotyktu |
| Galderma Laboratories, L.P. | $154.91 | 2019-2025 | Nemluvio, Aklief |
| Almirall LLC | $147.76 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $145.85 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.52 | 2019 | |
| Lifenet Health | $132.27 | 2024-2025 | Theragenesis Wound Matrix |
| Vyne Pharmaceuticals INC. | $120.31 | 2020-2021 | |
| Genentech USA, INC. | $102.27 | 2019-2021 | |
| Organogenesis INC. | $97.11 | 2021-2023 | Puraply |
| Mayne Pharma Commercial LLC | $94.71 | 2019 | |
| Pfizer INC. | $93.66 | 2019-2025 | |
| Bioventus LLC | $92.19 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.34 | 2024-2025 | Spevigo |
| Alnylam Pharmaceuticals INC. | $56.48 | 2023 | Givlaari |
| Genzyme Corporation | $50.69 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $50.46 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $33.08 | 2021-2023 | Valchlor |
| Convatec INC. | $32.62 | 2024 | |
| Merck Sharp & Dohme LLC | $30.77 | 2019-2023 | Keytruda |
| Aclaris Therapeutics, INC. | $27.08 | 2019 | |
| Mylan Institutional INC. | $20.25 | 2023 | Hulio |
| Sandoz INC. | $14.10 | 2024 | Hyrimoz |
| Epi Health, LLC | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.